Only limited real-life data are available on the effects of neutralizing monoclonal antibodies in high-risk patients who have early COVID-19 and do not require supplemental oxygen. We prospectively studied 217 patients infected by the delta variant who received casirivimab plus indevimab in a dedicated ambulatory unit created during our 4th COVID wave. Mean age was 64 years, 94% had at least one comorbidity, and mean duration of symptoms was 2.9 days. Oxygen requirement, hospitalization, and mortality rates were 10, 6, and 2.8%, respectively. These results suggest benefits of early administration of neutralizing antibodies in high-risk patients infected with the delta variant.
Only few data are available on real-life effectiveness of neutralizing monoclonal antibodies to avoid hospitalization in high-risk patients with early COVID-19 not requiring supplemental oxygen. Our study analyzed the efficacy of casirivimab plus indevimab to prevent unfavorable outcomes in these patients. A dedicated Hospital Day Unit was created to treat during our 4th COVID wave 217 patients infected by the Delta variant. Mean age was 64 years, 94% had at least one comorbidity, and mean duration of symptoms was 2.9 days. Oxygen request, hospitalization, and mortality rates were respectively of 10, 6, and 2.8%. These results suggest efficacy of neutralizing antibodies infused in a dedicated ambulatory unit created for high-risk patients infected with a Delta variant at an early stage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.